BioMarin to acquire rare disease drug developer Amicus for $4.8B

BioMarin (Nasdaq: BMRN) agreed to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction valuing Amicus at approximately $4.8 billion, expected to close in Q2 2026 subject to customary conditions.

The deal adds marketed products Galafold and Pombiliti+Opfolda, which generated $599 million in combined net product revenues over the past four quarters, and Amicus' U.S. rights to DMX-200 in Phase 3. BioMarin expects the acquisition to be accretive to Non-GAAP diluted EPS within 12 months and substantially accretive beginning in 2027. Financing will use cash on hand plus about $3.7 billion of non-convertible debt; BioMarin targets gross leverage <2.5x within two years. U.S. Galafold patent litigation was resolved with exclusivity expected through January 30, 2037.

https://www.stocktitan.net/news/BMRN/bio-marin-to-acquire-amicus-therapeutics-for-4-8-billion-expanding-s4p5v2wuwire.html